These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 12736045)
1. Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells. Wang H; Charles AG; Frankel AJ; Cabot MC Urology; 2003 May; 61(5):1047-52. PubMed ID: 12736045 [TBL] [Abstract][Full Text] [Related]
2. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Wang H; Maurer BJ; Reynolds CP; Cabot MC Cancer Res; 2001 Jul; 61(13):5102-5. PubMed ID: 11431347 [TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. Maurer BJ; Melton L; Billups C; Cabot MC; Reynolds CP J Natl Cancer Inst; 2000 Dec; 92(23):1897-909. PubMed ID: 11106681 [TBL] [Abstract][Full Text] [Related]
5. Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia. Morad SA; Davis TS; Kester M; Loughran TP; Cabot MC Leuk Res; 2015 Oct; 39(10):1071-8. PubMed ID: 26220867 [TBL] [Abstract][Full Text] [Related]
6. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Batra S; Reynolds CP; Maurer BJ Cancer Res; 2004 Aug; 64(15):5415-24. PubMed ID: 15289350 [TBL] [Abstract][Full Text] [Related]
7. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. Maurer BJ; Metelitsa LS; Seeger RC; Cabot MC; Reynolds CP J Natl Cancer Inst; 1999 Jul; 91(13):1138-46. PubMed ID: 10393722 [TBL] [Abstract][Full Text] [Related]
8. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes. O'Donnell PH; Guo WX; Reynolds CP; Maurer BJ Leukemia; 2002 May; 16(5):902-10. PubMed ID: 11986953 [TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies of the effects of the retinoid N-(4-hydroxyphenyl)retinamide on prostate cancer cell growth and apoptosis. Shen JC; Wang TT; Chang S; Hursting SD Mol Carcinog; 1999 Mar; 24(3):160-8. PubMed ID: 10204800 [TBL] [Abstract][Full Text] [Related]
10. Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells. Shimada K; Nakamura M; Ishida E; Kishi M; Yonehara S; Konishi N Mol Carcinog; 2002 Nov; 35(3):127-37. PubMed ID: 12410564 [TBL] [Abstract][Full Text] [Related]
11. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676 [TBL] [Abstract][Full Text] [Related]
12. Enhanced de novo ceramide generation through activation of serine palmitoyltransferase by the P-glycoprotein antagonist SDZ PSC 833 in breast cancer cells. Wang H; Giuliano AE; Cabot MC Mol Cancer Ther; 2002 Jul; 1(9):719-26. PubMed ID: 12479368 [TBL] [Abstract][Full Text] [Related]
13. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Lucci A; Han TY; Liu YY; Giuliano AE; Cabot MC Cancer; 1999 Jul; 86(2):300-11. PubMed ID: 10421266 [TBL] [Abstract][Full Text] [Related]
14. Fenretinide stimulates redox-sensitive ceramide production in breast cancer cells: potential role in drug-induced cytotoxicity. Rehman F; Shanmugasundaram P; Schrey MP Br J Cancer; 2004 Nov; 91(10):1821-8. PubMed ID: 15505623 [TBL] [Abstract][Full Text] [Related]
15. Spisulosine (ES-285) induces prostate tumor PC-3 and LNCaP cell death by de novo synthesis of ceramide and PKCzeta activation. Sánchez AM; Malagarie-Cazenave S; Olea N; Vara D; Cuevas C; Díaz-Laviada I Eur J Pharmacol; 2008 Apr; 584(2-3):237-45. PubMed ID: 18343365 [TBL] [Abstract][Full Text] [Related]
16. Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells. Messner MC; Cabot MC Cancer Chemother Pharmacol; 2011 Aug; 68(2):477-87. PubMed ID: 21072519 [TBL] [Abstract][Full Text] [Related]
17. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells. Roberson KM; Penland SN; Padilla GM; Selvan RS; Kim CS; Fine RL; Robertson CN Cell Growth Differ; 1997 Jan; 8(1):101-11. PubMed ID: 8993839 [TBL] [Abstract][Full Text] [Related]
18. N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing. Wang H; Maurer BJ; Liu YY; Wang E; Allegood JC; Kelly S; Symolon H; Liu Y; Merrill AH; Gouazé-Andersson V; Yu JY; Giuliano AE; Cabot MC Mol Cancer Ther; 2008 Sep; 7(9):2967-76. PubMed ID: 18790777 [TBL] [Abstract][Full Text] [Related]
19. p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action. Takahashi N; Watanabe Y; Maitani Y; Yamauchi T; Higashiyama K; Ohba T Int J Cancer; 2008 Feb; 122(3):689-98. PubMed ID: 17955489 [TBL] [Abstract][Full Text] [Related]